How does ihc work

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Immunohistochemistry (IHC) is a laboratory technique that uses antibodies to detect specific antigens in tissue sections, enabling visualization of protein expression patterns. Developed in the 1940s by Albert Coons, who first used fluorescent antibodies in 1941, IHC has evolved to include enzyme-based detection methods like peroxidase and alkaline phosphatase introduced in the 1960s. Today, IHC is a cornerstone of diagnostic pathology, used in over 90% of cancer diagnoses to identify tumor markers such as HER2 in breast cancer and PD-L1 in immunotherapy assessment.

Key Facts

IHC was pioneered by Albert Coons in 1941 using fluorescent-labeled antibodies
Enzyme-based detection methods like peroxidase were developed in the 1960s, increasing sensitivity
IHC is used in over 90% of cancer diagnoses worldwide
Common markers include HER2 (breast cancer), PD-L1 (immunotherapy), and Ki-67 (proliferation)
Automated staining systems can process up to 300 slides per day

Overview

Immunohistochemistry (IHC) is a critical diagnostic and research tool in pathology that visualizes specific proteins in tissue sections using antibody-antigen interactions. The technique originated in the 1940s when Albert Coons demonstrated that antibodies could be labeled with fluorescent dyes to detect antigens in tissues, publishing his landmark paper in 1941. Throughout the 1960s, researchers developed enzyme-based detection systems using horseradish peroxidase and alkaline phosphatase, which provided more stable results than fluorescence and enabled routine clinical use. By the 1980s, IHC had become standardized in pathology laboratories, with automated staining systems emerging in the 1990s that increased reproducibility. Today, IHC represents a multi-billion dollar market in diagnostic pathology, with applications spanning cancer diagnosis, infectious disease detection, and research into disease mechanisms.

How It Works

IHC involves several sequential steps beginning with tissue preparation: specimens are fixed in formalin, embedded in paraffin, and sectioned into thin slices (typically 4-5 micrometers thick). The sections undergo antigen retrieval, often using heat or enzymes, to expose epitopes masked by fixation. Primary antibodies specific to the target antigen are then applied and allowed to bind. Detection systems amplify the signal: indirect methods use secondary antibodies conjugated to enzymes like horseradish peroxidase or alkaline phosphatase. When substrate is added, these enzymes produce a colored precipitate at the antigen site. Chromogens include DAB (3,3'-diaminobenzidine) producing brown staining and AEC (3-amino-9-ethylcarbazole) producing red staining. Counterstaining with hematoxylin provides tissue architecture context. Automated systems now standardize these steps, controlling incubation times and temperatures to ensure consistent results across laboratories.

Why It Matters

IHC has transformed diagnostic medicine by enabling precise identification of disease markers that guide treatment decisions. In oncology, IHC determines hormone receptor status in breast cancer (estrogen and progesterone receptors), HER2 overexpression for targeted therapy, and PD-L1 expression for immunotherapy eligibility. Beyond cancer, IHC detects infectious agents like viruses and bacteria in tissues, identifies amyloid deposits in neurodegenerative diseases, and characterizes immune cell infiltrates in autoimmune disorders. The technique's clinical impact is substantial: accurate IHC results directly influence therapeutic choices, with studies showing that proper HER2 testing affects treatment outcomes for approximately 20% of breast cancer patients. IHC also advances research by mapping protein expression patterns in development, disease progression, and drug response studies.